aparat aparat telegram1  ar en fa

ساعت کار مرکـز :

شنبه تا 4شنبه: ساعت 8 الی 22 - 5شنبه ها: ساعت 8 الی 14

instagram takipçi satın al indoXploit shell PUBG Lite

درمان سرطان پستان

تجویز داروهای جدید دردرمان سرطان پستان :

Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials.
Review article
Rydén L, et al. Breast. 2016.
Show full citation

Abstract
Tamoxifen (TAM) and aromatase inhibitors (AI) are adjuvant therapy options for postmenopausal women with estrogen receptor positive (ER+) breast cancer. This systematic review of seven randomized controlled studies comparing TAM and AI, and one study comparing extended therapy with an AI with placebo after about 5 years of tamoxifen, aims to assess long-term clinical efficacy and adverse events. The literature review was performed according to the principles of the Cochrane Collaboration. The search included common databases up to 2013-01-14. Studies of high or moderate quality were used for grading of evidence. Revman™ software was utilized for meta-analyses of published data. Disease free survival (DFS) and overall survival (OS) were improved with AI monotherapy compared to TAM with high and moderate quality of evidence respectively. Sequenced therapy with AI → TAM (or vice versa) improved DFS compared with TAM with moderate quality of evidence, but did not improve OS (low quality of evidence). However, if only studies on sequenced AI therapy with randomization before endocrine therapy were considered, no improvement of DFS could be found. Fractures are more frequently associated with AI whereas the risk of endometrial cancer and venous thromboembolism are higher with TAM. For cardiovascular events no difference was found between AI (mono- or sequenced therapy) and TAM, whereas sequenced therapy compared with AI had lower risk of cardiovascular events (moderate level of evidence). AIs are superior to TAM as adjuvant hormonal therapy for postmenopausal ER-positive breast cancer. TAM can be considered for individual patients due to the different toxicity profile compared with AI. Cardiovascular events related to AI treatment deserve further attention.

Copyright © 2016 Elsevier Ltd. All rights reserved.
PMID 27017249 [PubMed - as supplied by publisher]
Previous
Citation 2 of 104738
Back to results Next
Similar articles

Adjuvant aromatase inhibitor therapy: outcomes and safety.
Review article
Janni W, et al. Cancer Treat Rev. 2010.
Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Review article
Jahanzeb M, et al. Clin Ther. 2007.
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Review article
Gibson LJ, et al. Cochrane Database Syst Rev. 2007.
Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Hind D, et al. Health Technol Assess. 2007.
Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Review article
Berry J, et al. Clin Ther. 2005.
See all
Full website NIH NLM NCBI Help

خواندن 1224 دفعه
شنبه, 04 ارديبهشت 1395 14:33 چاپ

نظرات (0)

تاکنون نظری برای این مطلب ارسال نشده است.

نظر خود را اضافه کنید.

در قالب میهمان نظر خود را ارسال کنید. ثبت نام کنید یا وارد شوید به حساب کاربریتان.
0 Characters
پیوست ها (0 / 3)
Share Your Location

اطلاعات مرکز

آدرس: اصفهان - خیابان شمس آبادی-چهارراه قصر-مجتمع قصرنور-طبقه 5-واحد501
تلفن‌های تماس: 32240047-031 - 09130748424
تلفن گویا: 9730361
فکس  : 03132240047
کدپستی: 3165844567
ایمیل: info@novintahlilgaran.com

map

رفتن به بالا